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Resumo 
Introdução: Apesar das diferentes abordagens terapêuticas atualmente existentes para o 
tratamento do hematoma subdural crónico (HSDC), a recidiva pós-cirúrgica mantém-se 
uma complicação frequente. O objetivo deste estudo é identificar fatores de risco para 
recidiva de HSDC. 
Métodos: Realizámos um estudo caso-controlo retrospetivo com uma série de casos 
consecutivos de HSDC tratados cirurgicamente. Relacionámos as seguintes variáveis 
com o risco de recidiva de HSDC: género, idade, localização do HSDC, terapêutica com 
antiagregantes ou anticoagulantes, trombocitopénia e utilização de dreno pós-operatório.  
Resultados: Dos 257 doentes analisados, 40 (15.6%) apresentaram recidiva do HSDC. 
Verificou-se maior taxa de recidiva nos doentes mais jovens (p <0.05) e tendência a 
recidiva nos doentes medicados com anticoagulantes e naqueles em que não foi 
utilizado dreno subdural pós-operatório (p <0.2). As outras variáveis não se associaram 
a maior risco de recidiva. Os doentes com recidiva apresentaram maior morbilidade (p 
<0.05). 
Conclusões: Na série analisada, a recidiva de HSDC esteve associada a maior 
morbilidade pós-cirúrgica, e a idade mais jovem constituiu um fator de risco para 
recidiva. A medicação habitual com anticoagulantes e a ausência de dreno subdural pós-
operatório poderão constituir outros fatores de risco.   
Palavras-chave: Hematoma subdural crónico; recidiva; idade; anticoagulantes; dreno 
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Abstract 
Introduction: In spite of the current different therapeutic approaches for the treatment 
of chronic subdural hematoma (CSDH), post-operative recurrence remains a frequent 
complication. The aim of this study is to identify risk factors for recurrence of CSDH. 
Methods: We conducted a retrospective case-control study with a series of consecutive 
surgically treated cases of CSDH. The following variables were analyzed as potential 
risk factors for recurrence of CSDH: gender, age, location of CSDH, treatment with 
antiaggregants or anticoagulants, thrombocytopenia and use of postoperative drain. 
Results: From a total of 257 patients analyzed, 40 (15.6%) presented with recurrent 
CSDH. We observed a higher recurrence rate in younger patients (p <0.05) and a 
tendency towards recurrence in patients treated with anticoagulants and in those who 
did not receive a subdural post-operative drain (p <0.2). The other variables were not 
associated with higher risk of recurrence. Patients with recurrence presented higher 
morbidity (p <0.05).   
Conclusions: In this series, recurrence of CSDH was associated with increased post-
operative morbidity, and younger age was a risk factor for recurrence. Usual medication 
with anticoagulants and the absence of subdural post-operative drain may represent 
other risk factors. 
Key-words: Chronic subdural hematoma; recurrence; age; anticoagulants; drain 
  
3 
 
List of abbreviations: 
- ACE: angiotensin converting enzyme  
- aPTT: activated partial thromboplastin time 
- BHC: burr-hole craniostomy  
- CHLO: Centro Hospitalar Lisboa Ocidental 
- CSDH: chronic subdural hematoma 
- CT: computerized tomography 
- DBC: dural border cell 
- GCS: Glasgow coma scale 
- INR: international normalized ratio 
- MRI: magnetic resonance imaging  
- PlGF: placental growth factor 
- SD: standard-deviation 
- SDH: subdural hematoma 
- TDC: twist-drill craniostomy 
- VEGF: vascular endothelial growth factor 
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I. Introduction 
1. Definition 
A subdural hematoma (SDH) is a collection of blood between the inner layer of the 
dura mater and the arachnoid mater. It is one of the most common type of traumatic 
intracranial mass lesion [1]. The cause of this neurosurgical entity is frequently the 
tearing of the bridging veins, which connect the cortical surface of the brain to a dural 
sinus [1], after a head trauma [2]. 
SDHs may be classified as acute, subacute or chronic, based on the amount of time 
elapsed since the beginning of the bleeding, which is important to determine the best 
treatment to each type [3]. It is generally considered that SDHs are acute until the first 
72 hours after the injury, subacute between 3-7 days, and chronic when they are ≥ 3 
weeks [1, 3]. While an acute SDH occurs usually in younger adults after a major 
trauma, a chronic subdural hematoma (CSDH) affects mainly the elderly after a less 
important injury and it takes a few weeks or months until it becomes clinically apparent.  
 
2. Epidemiology 
CSDH is one of the most frequent diagnoses in neurosurgery. The incidence of 
CSDH is estimated at 1.7-18 per 100.000 people, increasing to 58 per 100.000 people in 
patients above 65 years old [1, 4-6]. It has a peak incidence between the sixth and the 
seventh decades of life, and the average age of patients is approximately 63 years old [1, 
2]. As the number of old people increases in population, the incidence of CSDH is 
expected to double by the year 2030 [1, 4]. CSDH affects predominantly men with a 
male-to-female ratio of 3:1 [1, 7]. Recurrence of CSDH after the treatment is one of the 
most frequent complications with a median incidence of 15% reported in the literature, 
ranging from 0 to 30% [1]. CSDHs are bilateral in 20-25% of the cases [1]. Bilateral 
SDHs are more common in infants, because the adhesions existing in the subdural space 
are absent at birth and develop with aging [1]. 
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3. Pathophysiology, etiology and risk factors 
A CSDH is a delineated blood collection in the space between the dura mater and 
the arachnoid, enclosed within a hematoma capsule [8]. The subdural space is a virtual 
space that does not exist in physiological conditions, because the dura and the arachnoid 
are bound by a layer of dural border cells (DBC), made especially of fibroblasts [1, 4, 
9]. This layer is relatively loose, as it has no tight junctions or intercellular collagen, and 
it is crossed by the bridging veins. The tearing of these veins causes a leakage of blood 
into the DBC layer and creates an acute SDH [1, 8, 9]. The incapacity of resorption of 
small acute SDHs will result in a CSDH [1, 2]. The shearing of the DBC layer generates 
an inflammatory reaction by the fibroblasts, which appears to be the initial stimulus of 
the pathophysiology of CSDH [9]. In 20-30% of the cases, the cause of the SDH is an 
arterial rupture [4]. 
The tearing of the bridging veins seems to be, therefore, the main cause of CSDH. 
This tearing can have a non-traumatic origin, such as cerebrovascular lesions (p.e. 
arteriovenous malformations), infections, brain tumors (p.e. convexity meningiomas) 
[8], or a traumatic one, which is definitely more frequent. Traumatic causes include 
direct head injuries, but also indirect trauma, in which the point where the traumatic 
force is applied is not in the cranium, but, due to sudden acceleration and deceleration 
forces, the brain is affected. Head trauma may occur in several situations, such as falls, 
previous neurosurgery or during labor [10]. The majority of CSDHs are caused by 
trivial mild indirect head trauma [1, 2, 11]. Elderly and male gender are considered risk 
factors of CSDH, as these groups have a higher tendency to head injury [1, 12].   
 In addition to these causes, many factors increase the vulnerability of the bridging 
veins and the risk of developing a CSDH, such as cerebral atrophy (a common and 
physiological condition in the elderly), deformation of the cranial vault during its 
development, and low intracranial pressure [8, 12]. When there is brain atrophy, the 
arachnoid is dragged away from the dura mater, which remains attached to the skull, 
stretching the bridging veins passing through the subdural space [1].  
Hematogenic factors play also an important role in CSDH’s pathophysiology, as 
they may increase the patient’s tendency to bleed. Coagulopathies, which includes 
medical conditions having a bleeding tendency, such as liver cirrhosis (p.e. by chronic 
alcoholism), chronic renal failure, hematologic disorders, chemotherapy, but also 
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therapy with anticoagulants or antiplatelet agents are well-known risk factors of CSDH 
[10, 11].  
After the tearing of the bridging veins, the blood leakage and the inflammatory 
reaction by the fibroblasts of the DBC layer, the blood collection undergoes a series of 
changes, with leucocyte infiltration, neoangiogenesis, microhemorrhage, local 
coagulopathy, collagen synthesis, fibrin deposition and excessive local fibrinolysis and 
anticoagulation with liquefaction of the hematoma [1, 9]. The development of CSDH is 
a dynamic process [9].  
After approximately two weeks, an inner (cortical) and outer (dural) neomembrane 
is formed within the DBC layer [1]. The thicker outer membrane corresponds to the 
meningeal layer of the dura mater, and it develops into several stages until it becomes 
extremely inflamed and vascularized by giant capillaries, which present an incomplete 
basement membrane and allow an easy and repeated bleeding [8, 9].  
The factors responsible for the maintenance and growth of CSDH are still unclear 
and have been studied for decades, leading to different theories. One of the most 
currently accepted theories is the microbleeds theory, in which the growth of the 
hematoma is explained by recurrent microhemorrhages from the giant and fragile 
capillaries of the neomembrane [1]. The anticoagulant and profibrinolytic theory 
postulates that there is an excess of fibrinolytic and anticoagulant factors in the 
neomembrane itself, which causes liquefaction of the subdural blood clots and 
continuous hemorrhage from the sinusoidal vessels [1, 8, 9]. An infiltration of 
eosinophils in the outer membrane, observed in several studies, may also contribute to 
the local hyperfibrinolysis and recurrent bleedings, as their granules contain 
plasminogen [9]. The inflammatory and growth factors theory suggests that the 
inflammation around the CSDH is accompanied by a high concentration of vascular 
endothelial growth factor (VEGF) and placental growth factor (PlGF) [1, 9]. These 
angiogenic factors allow continuous formation of neovessels, which are 
hyperpermeable, causing the expansion of the hematoma [1, 9]. Probably the multiple 
factors described in these three theories cause the maintenance and enlargement of 
CSDH [1]. 
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4. Clinical presentation 
Most commonly, the presentation is subacute or chronic, after a minor head injury. 
The CSDH develops slowly, under low pressure, and it takes a variable period until it 
becomes clinically apparent. The severity of symptoms vary from mild (confusion, gait 
disturbance, dementia, language problems, incontinence) to severe (hemiplegia, aphasia, 
seizures, coma), and general symptoms are often present (headache, fatigue, nausea and 
vomiting, vertigo) [1, 13, 14].  
In a study with 500 patients with CSDH, the most common symptoms were gait 
disturbance (63%), hemiparesis (58.6%) and headache (38.2%) [10]. Dementia, 
incontinence, consciousness disturbance, vomiting, seizures, anisocoria and motor 
aphasia were also registered [10]. Headache was more frequent in younger patients, and 
dementia occurred more often in bilateral CSDHs [10]. In another study, with patients 
over 90 years old, the leading symptoms were hemiparesis and gait disturbance, 
followed by disturbance of consciousness and speech disturbance [15]. 
Usually, the younger the patient is, more severe and acute the symptoms are, 
because of the age-related cerebral atrophy that allows the hematoma to reach a larger 
size without triggering any neurologic signs [1, 16]. Because CSDH affects mainly the 
elderly, the severe symptoms are less common than the mild ones. Patients with CSDH 
can be asymptomatic, making the diagnosis difficult. 
 
5. Diagnosis 
For the diagnosis of CSDH it is fundamental to have a high index of suspicion [2]. It 
should be considered in any patient presenting one or more symptoms above described, 
with or without a history of trauma. After collecting clinical history and performing 
physical examination, brain imaging should be performed. The mainstay for diagnosis 
of CSDH is computerized tomography (CT) [1, 2, 7, 8]. A typical CT scan image of a 
CSDH is a crescent-shaped iso- to hypodens collection between the inner table of the 
skull and the surface of the affected cerebral hemisphere [1, 17].  
As CSDH is a dynamic lesion, its appearance on CT scans varies with its time. 
During the acute phase of the hematoma (< 3 days), the blood collection is hyperdens, 
becoming isodens in its subacute phase (3 days to 3 weeks) and hypodens in the chronic 
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phase (≥ 3 weeks) [1, 2]. It is not rare to find a heterogeneously dens image of the 
hematoma, because of the repeated microhemorrhages [2]. Subacute hematomas may be 
harder to identify, as they are isodens. The location of the CSDH is usually in the 
fronto-parietal region over the convexity, but may also occur in the cranial base [17].  
Besides the hematoma itself, other CT features can be found due to his mass effect: 
sulcal effacement, midline shift and obliteration of the basal cisterns [2]. These signs 
can be absent when there is a bilateral CSDH.  
Magnetic resonance imaging (MRI) is more accurate than CT and, therefore, it may 
be required in patients with isodens subacute, bilateral, or small hematomas [2]. MRI 
allows for precise evaluation of the hematoma thickness, its margins, and the 
identification of its membranes and internal structures, even in small CSDHs [1]. 
Nevertheless, CT is preferred over MRI, because of its accessibility, shorter study time, 
and lower cost [1, 2, 8]. Other exams, such as contrast-enhanced CT, cerebral 
angiography, and scintigraphy are usually not required.  
 
6. Management 
The treatment of CSDH has been studied over the years and it is still subject of 
hundreds of current studies. Both conservative and surgical therapies have been 
proposed, but recurrence rates and complications remain an issue and are not fully 
understood. Today, it is widely accepted that the choice of treatment will depend on the 
clinical presentation and the radiographic appearance of the hematoma [1, 4]. Therefore, 
an asymptomatic patient with a minor CSDH is best managed conservatively or 
remaining under monitoring, whereas a symptomatic patient with a large hematoma 
would rather benefit from surgical evacuation. The treatment of patients with CSDH 
with mass effect, but without neurologic symptoms, is controversial, and there is no 
sufficient data to support the decision [1]. The hematoma’s size may play an important 
role in the decision to perform surgery, but evidence-based absolute cutoffs sizes still do 
not exist [1]. Generally accepted cutoffs for the indication of surgery are maximum 
hematoma thickness exceeding that of the skull, or greater than 1 cm [1]. 
Some of the conservative therapies of CSDH that have been suggested are the use of 
corticosteroids, angiotensin converting enzyme (ACE) inhibitors, osmotic diuretics such 
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as mannitol, and tranexamic acid [1]. Spontaneous resolution of CSDHs has also been 
reported [18, 19]. Further research is clearly necessary, before one can truthfully rely on 
these therapies. On the other hand, surgical drainage is considered an effective 
treatment, and it can be achieved with twist-drill craniostomy (TDC), burr-hole 
craniostomy (BHC), or craniotomy [20]. These are the most common surgical 
procedures, and for each one numerous variations have been developed. The lack of 
high quality and well performed studies makes it difficult to identify the most effective 
surgical technique for CSDH [1]. 
With TDC, a small opening of 5-10 mm in the scalp is produced and a twist drill 
hole is placed in the direction of the longitudinal axis of the hematoma [1, 3]. A catheter 
is inserted into the subdural space, and it is removed when at least 20% of the 
hematoma is drained and/or when there is clinical improvement, which occurs in mean 
of 2.1 days [3]. A low pressure shunt valve can be introduced to prevent air reflux [3]. 
The decompression of the brain occurs more slowly than in other surgical procedures, 
avoiding the presumed rapid pressure shifts that may be associated with complications, 
such as intracerebral hemorrhage [3]. TDC is less invasive and can be performed under 
local anesthesia at the bedside. Therefore, it is an attractive option for patients with 
several comorbidities who are poor surgical candidates [4]. However, this technique is 
most effective in cases of completely liquefied blood collections with no membranes, 
and it can be associated with an increased risk of infection when performed at the 
bedside [4]. There are varying results between studies that compared outcomes of TDC 
vs. BHC or craniotomy. One study, in 1997, concluded that TDC had lower mortality 
and reoperation rates than BHC [21]. More recent studies revealed that TDC had a 
similar or even superior mortality rate and a significantly higher recurrence rate, when 
compared to BHC [4, 20].  
BHC allows a larger opening (5-30 mm) in the scalp and it is usually performed 
under general anesthesia [4, 20, 22]. BHC seems to be, in the present time, the most 
common treatment for CSDH [4, 19, 20]. It has the best cure to complication ratio, and 
it appears to be more effective in treating recurrent hematomas than TDC [23]. There 
are many variations of this technique, regarding the number of burr-holes (one or two 
are the most common options), the need of intraoperative irrigation, the use of closed-
system drainage after the surgery or not, the localization of the drain (subgaleal or 
subdural), and the post-operative procedures [4]. Despite the large number of studies 
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comparing the results achieved with these different variations of BHC, the most 
efficient method remains unclear. It seems that two burr-holes are as effective as one 
burr-hole in the CSDH management [17, 24]. Evidence favors the use of irrigation fluid 
to wash out the hematoma, even though it can increase the risk of pneumocephalus and 
infection [7]. Regarding drainage use, it is becoming more evident that inserting closed-
system drainage after surgery improves the patient’s outcome, by decreasing recurrence 
and mortality rates [20]. When comparing subdural and subgaleal drains, no significant 
difference in recurrence and functional outcome was found, at least at 3 months after 
surgery, but there was a tendency of lower rate of recurrence after subdural drain and a 
tendency of lower mortality after subgaleal drain [25]. Post-operative procedures such 
as maintaining a lying flat position and adequate intravenous hydration have been 
thought to reduce recurrence rates, but the complications of immobility (infections, deep 
venous thrombosis, etc.) also need to be considered [4, 26]. 
Craniotomy requires general anesthesia, and involves the turning of a larger (> 30 
mm) free bone flap, irrigation and evacuation of the CSDH, following the replacement 
of the flap [7]. This was the treatment of choice until the mid-1960s, because it offered 
the surgeon a maximal exposure of the brain and the ability to excise membranes in the 
subdural space, allowing the brain re-expansion [7, 20]. This is the most invasive option 
for the treatment of CSDH, requires a greater operative time, entails a greater blood 
volume loss [4] and is associated with higher rates of morbidity [6, 14, 23]. Despite 
these, craniotomy is still the best option for evacuation of recurrent organized, calcified 
and with several thick membranes CSDHs, and for primary evacuation of a CSDH 
presenting a substantial acute component [4, 7, 14]. 
Many other surgical techniques have been proposed, such as oxygen instillation, 
middle meningeal artery embolization, ommaya reservoir implantation with repeated 
punctures and subduroperitoneal shunting [4]. Further studies are needed in order to 
recommend the generalized adoption of these procedures. 
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7. Post-operative complications, recurrence rates and outcome 
Possible post-operative complications include: failure of the brain to re-expand 
and/or reaccumulation of the subdural fluid, leading to recurrence of CSDH (0-30%) 
[1]; seizures (1-23%) [1, 3]; intracerebral hemorrhage (0,7-5%) [1, 3]; infections 
(surgical site infection, subdural empyema, etc.) (2%) [1, 3] and tension 
pneumocephalus (0-10%) [1, 3]. Non-surgical complications related to the 
hospitalization (hospital-acquired infections, venous thromboembolism) and to the 
patient’s previous diseases can always occur. All surgery-related complications are 
more common in elderly, polymorbid and debilitated patients [3].  
The most important complication of CSDH is recurrence needing a repeated 
drainage [7]. Recurrence rates vary widely in literature, but the most contemporary 
consensus is that the reoperation rate is about 10-20% [7]. The risk factors for 
recurrence, discussed in several studies, are variable and include: age, alcoholism, 
diabetes, cerebral atrophy, use of anticoagulation or antiplatelet medication, poor 
clinical state at presentation, poor Glasgow coma scale (GCS) and Glasgow outcome 
scale, bilateral CSDH, highly dens hematoma on CT, thick hematoma on CT or MRI, 
intraoperative visualization of defective brain re-expansion and thick membranes, post-
operative midline shift, pneumocephalus and presence of septum or multiple 
membranes in the subdural space [1, 7, 27, 28]. Intraoperative insertion of a closed 
system drainage after surgical procedure is the only proven factor that reduces 
recurrence rates [1]. 
Mortality in patients with CSDH varies from 0–32%, and morbidity from 0–25% 
[7]. Important prognostic factors include age, GCS score or clinical state at presentation, 
presence of medical comorbidities and coagulopathy [7]. In a series of 500 patients 
treated with BHC with closed-system drainage, 89.4% had a good recovery, 8.4% 
showed no change, 2.2% worsened and 1.2% died [10].  
 
8. Objective 
The aim of this study is to identify risk factors for recurrence in a series of 
surgically treated CSDHs.  
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II. Materials and methods 
1. Study design 
We conducted a retrospective case-control study using data from all patients 
consecutively operated for chronic or subacute SDH at Centro Hospitalar Lisboa 
Ocidental (CHLO), which includes Hospital Egas Moniz and Hospital São Francisco 
Xavier, in Lisbon, Portugal, between January 2011 and December 2014. The study was 
made by a 6
th
 year medicine student as his master’s degree final project, under 
orientation of a 5
th
 year Neurosurgery Resident at CHLO. Patients’ data was analyzed 
by the authors, using the institutional computing database and the surgical reports book, 
between February and October 2015. Patients were informed, during their 
hospitalization, that their clinical data could be used for medical research. 
Patients admitted in the two aforementioned hospitals presenting symptoms 
consistent with chronic or subacute SDH underwent a CT scan and if the diagnosis was 
confirmed they were hospitalized. We defined CSDH as a hypodens blood collection in 
the subdural space, and subacute SDH when the blood collection was isodens. In this 
study, both conditions were included and they were simply designated CSDH. Surgery 
was performed whenever a patient with a CSDH scan was symptomatic. Presenting 
symptoms included headaches, gait disturbances, confusion, hemiparesis, aphasia, 
disorientation and seizures. A BHC, under general anesthesia, was performed as the 
standard surgical technique. Exclusion criteria were patients presenting concomitantly 
chronic and acute SDHs. If missing data was not possible to complete by clinical record 
consultation, patients were excluded from statistical analysis. 
We collected the following data for each patient at admission: gender, age, clinical 
presentation (GCS and presence of focal neurologic deficits), usual medication 
(antiplatelet or anticoagulant drugs, ACE inhibitors) and laboratory tests (platelet count, 
international normalized ratio [INR], activated partial thromboplastin time [aPTT]). We 
also gathered information about the surgical procedure and outcomes after surgery 
(recurrence, morbidity and mortality). Recurrence was defined as need of a second 
surgical procedure, in the first two months after surgery, due to persistence or re-
accumulation of CSDH in the same location, proven by CT scan. The criteria for re-
operation were worsening or recurrence of neurological deficits [29]. For patients who 
had recurrent CSDH (undergoing, therefore, at least two surgeries), we only analyzed 
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their first procedure. Mortality included death in the first month after surgery. Morbidity 
was defined as any clinical complication occurring after surgery, other than recurrence 
or death. Data regarding follow-up after discharge was collected from out-patient clinics 
records. Follow-up appointments were usually held at 1, 3 and 6 months after surgery.  
 
2. Hospitalization and operative method 
Essentially the same surgical technique was employed for CSDH by the several 
neurosurgeons of CHLO. Hematoma evacuation was done via one or two burr-holes, 
and irrigation was made with isotonic saline, under sedation or general anesthesia. Two-
burr-hole technique was the most used. Closed system drainage (subgaleal or subdural) 
was left in place when the risk of recurrence was predicted as higher. If a patient taking 
antiaggregants or anticoagulants was clinically stable, the surgery was postponed until 
the washout of the medication, but during that period patients were admitted and closely 
monitored. If an urgent surgery was necessary, the adequate correction, either with 
platelets or coagulation factors, was done. 
After surgery, patients received adequate intravenous hydration and were maintained 
in a lying flat position, to help the brain re-expansion. If a drain was left in place, it was 
removed 48-72h after surgery, usually after a new CT evaluation.  
Instead of BHC, craniotomy was performed mostly to treat recurrent cases. 
 
3. CT surveillance 
All patients underwent a CT scan to confirm the diagnosis prior to the operation. 
Routine postoperative CT was performed before drain removal (or 72h after surgery, if 
no drain was placed), and repeated before each medical appointment, until no further 
control was needed.  
 
4. Statistical analysis 
The variables analyzed as being potential risk factors for CSDH recurrence were 
age, gender, presence of bilateral CSDH, medication with antiplatelet agents or 
anticoagulants before surgery, presence of thrombocytopenia before surgery, absence of 
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post-operative drain, either subdural or subgaleal. For each variable p value with 95% 
confidence interval was determined using Fisher’s exact test (two-tailed). For age, 
analysed as a continuous variable, the τ test was used. These calculations were obtained 
using GraphPad
®
 online software. A trend was defined when p <0.2 [30]. 
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III. Results 
The trial profile is shown in Figure 1. A total of 261 patients were operated for 
CSDH during this period. Four patients were excluded from the study: 2 due to missing 
data and 2 because they presented with both chronic/subacute and acute SDH. Of the 
257 patients analyzed, 40 had recurrence – recurrence rate of 15.6%. Most patients 
(251) underwent BHC, whereas 6 were treated with craniotomy.  
The characteristics of the patients are noted in Table 1. Approximately 63% of our 
patients were male and mean age was 76 years old (ranging from 37 to 98, median 78). 
Mean age among men was slightly lower than among women (75 vs. 77 years old, 
respectively), and mean age among patients without recurrence was higher than among 
patients with recurrence (77 vs. 73) (see also Table 2). The number of left- and right-
sided CSDHs was similar (43% vs. 39%, respectively), and 18% were bilateral. 35% of 
the patients were taking antiplatelet drugs (aspirin, clopidogrel, ticlopidine or triflusal) 
and 12% were under anticoagulants (warfarin, acenocoumarol or enoxaparin). 19% of 
the patients had thrombocytopenia at the time of admission. Considering the patients 
who underwent BHC, nearly 65% were operated without using a post-operative 
drainage system, whereas in 23% a subdural and in 12% a subgaleal drain was left in 
place. We obtained a mortality and morbidity rate of 7% and 11%, respectively. Most of 
the deaths occurred due to aggravation of underlying clinical diseases or due to hospital-
acquired infections (mainly pneumonia). Main causes of morbidity were persistent 
neurologic deficits, wound infection, empiema or suture dehiscence, symptomatic 
cerebral hemorrhage (intraparenchymal or acute SDH) requiring further management 
and seizures. We only considered seizures as a morbidity cause when at least one 
episode occurred after hospital discharge after surgery. 
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261 surgeries 
performed to treat 
CSDH 
257 surgeries analyzed 
217 surgeries without 
recurrence  
40 surgeries with 
recurrence  
 5 craniotomies 
 212 BHC 
o40 bilateral hematomas 
 1 craniotomy 
 39 BHC 
o7 bilateral hematomas 
 2 performed to treat concomitantly 
CSDH and other hematomas’ type 
 2 due to missing data 
4 surgeries 
excluded 
Figure 1 – Trial profile. BHC, burr-hole craniostomy; CSDH, chronic subdural hematoma 
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Table 1 – Patients characteristics and outcomes. Total n was 257, except for the following variables: 
antiaggregation and anticoagulation therapy (total n = 254), thrombocytopenia (total n = 227) and burr-hole 
craniostomy (total n = 249), due to missing data. SD, standard-deviation. 
 
 
Table 2 shows the association between the studied variables and recurrence of 
CSDH. Mean age among patients who had recurrent CSDH and were, therefore, 
reoperated was significantly lower than among those who did not have recurrent CSDH 
(p = 0.03). Patients taking anticoagulants showed a trend towards a higher risk of 
recurrence (p = 0.19). On the other hand, the use of subdural drainage showed a trend as 
protector factor against recurrence, as patients who did not receive a post-operative 
drainage system or receive a subgaleal drain had a higher recurrence rate when 
compared to those who received a subdural drain (p = 0.14). Patients who had recurrent 
CSDH had also higher morbidity rate (p = 0.03), but not higher mortality rate. Gender, 
bilateral hematomas, medication with antiplatelet agents, thrombocytopenia and 
subgaleal drain use did not seem to influence recurrence of CSDH in our series.  
 
 
 
 
Total n  257  
Gender 
Male n (%) 163 (63.42%) 
Female n (%) 94 (36.58%) 
Mean age years ± SD 76.04 ± 11.16 
Hematoma location 
Left n (%) 110 (42.8%) 
Right n (%) 100 (38.91%) 
Bilateral n (%) 47 (18.29%) 
Antiaggregation therapy n (%) 89 (35.04%) 
Anticoagulation therapy n (%) 30 (11.81%) 
Thrombocytopenia n (%) 43 (18.94%) 
Burr-hole 
craniostomy 
With subdural drain n (%) 56 (22.49%) 
With subgaleal drain n (%) 30 (12.05%) 
Without drain n (%) 163 (65.46%) 
Mortality n (%) 18 (7%) 
Morbidity n (%) 29 (11.3%) 
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Table 2 – Factors related to recurrence of chronic subdural hematoma. SD, standard-deviation. 
 
  
Variables 
With recurrence n 
(%) 
Without 
recurrence n (%) 
p value 
Gender 
Male n (%) 29 (72.5) 134 (61.75) 0.22 
Female n (%) 11 (27.5) 83 (38.25) 0.22 
Mean age years ± SD 72.50 ± 12.26 76.69 ± 10.86 0.03 
Hematoma location 
Left n (%) 16 (40) 94 (43.32) 0.73 
Right n (%) 17 (42.5) 83 (38.25 0.6 
Bilateral n (%) 7 (17.5) 40 (18.43) 1 
Antiaggregation therapy n (%) 16 (41.03) 73 (33.95) 0.47 
Anticoagulation therapy n (%) 7 (17.95) 23 (10.7) 0.19 
Thrombocytopenia n (%) 6 (16.67) 37 (19.37) 0.82 
Burr-hole 
craniostomy 
Without subdural 
drain n (%) 
34 (87.18) 159 (75.71) 0.14 
Without subgaleal 
drain n (%) 
33 (84.62) 186 (88.57) 0.43 
Without drain n 
(%) 
28 (71.7949) 135 (64.2857) 0.46 
Mortality n (%) 2 (5) 16 (7.37) 0.75 
Morbidity n (%) 9 (22.5) 20 (9.22) 0.03 
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IV. Discussion 
1. Interpretation of the results 
 
We obtained a recurrence rate of 15.6%, which is similar to other reports [1, 30-33]. 
Our series was also comparable to previous studies in terms of gender and age 
prevalence, with a mean age of 76 years old and a male predominance [31, 33]. Gender 
was not associated with higher recurrence rates, which is in agreement with other works 
[28, 32]. Surprisingly, mean age among patients who had recurrence of CSDH was 
lower than among those who did not have recurrence, and this difference was 
statistically significant. Borger et al. showed that patients above the age of 85 presented 
lower recurrence rates, yet carried a greater risk for other complications [34]. Another 
study also found a lower mean age among patients in the recurrent group when 
comparing to those in the non-recurrent group, but, unlike our result, the difference was 
not significant [35]. We did not find any article reporting younger age as a risk factor 
for recurrent CSDH. Our unexpected result could be explained by the fact that we only 
considered as recurrent CSDH when the hematoma was reoperated on (see Materials 
and methods), and reoperation might have been more frequent among younger patients. 
Although current data suggests that surgical treatment is safe in elderly patients [34], 
there are always operation-associated risks, and we might have tried to follow a more 
conservative strategy among those who were older. The definitions of recurrence are 
highly variable between studies, even in the subgroup of those looking specifically for 
this outcome [36], and this heterogeneity may explain the discrepancy of results in the 
literature.  
Nearly 18% of the CSDHs were bilateral, which is consistent with earlier reports 
[10, 31], as well as a slightly more frequent location of CSDH on the left side (43%) 
[31]. Although some authors consider bilaterality a risk factor for recurrence of CSDH 
[37], others did not find the same association [33]. Like the latter, we did not observe an 
increased recurrence rate in bilateral CSDHs. One study concluded that bilateral CSDHs 
were independent predictors for reoperation due to surgical complications [30], but not 
necessarily due to recurrence of the hematoma.  
In our study, a considerable number of patients were taking antiplatelet or 
anticoagulant medication at admission (35% and 12%, respectively), suggesting that 
these drugs are important risk factors for CSDH. Attention should be paid on the 
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possible adverse effects of these medications, considering the fact that there is an 
increasing number of users, especially among the elderly [28]. In our series, antiplatelet 
agents were not associated with an increased risk of recurrence. Similar results are 
found in other reports [28, 31, 33, 37]. Wada et al. reported a significant influence of 
antiplatelet therapy on the recurrence of CSDH, but not if the surgery was delayed for 
more than 3 days after discontinuation of the drug [29], which can explain our 
observation. 
We found that usual treatment with anticoagulant drugs before surgery had a trend 
towards a higher recurrence rate. Schwarz et al. also reported that patients receiving 
vitamin K antagonists had a tendency towards a higher risk of surgically-relevant 
hematoma re-accumulation [30]. Other studies showed a significant association between 
the use of anticoagulants and higher recurrence rates [28, 33]. Mori and Maeda 
demonstrated that the administration of anticoagulant agents was significantly 
correlated with poorer brain re-expansion after hematoma evacuation [10], which could 
lead to higher risk of re-accumulation. However, results are conflicting, and some of the 
studies that reported no association with antiplatelet agents and recurrence, also did not 
find an association between anticoagulants and recurrence [31, 37]. 
In our study, there was no association between the presence of thrombocytopenia at 
admission and recurrence rate after surgery. This lack of association can be easily 
explained when we consider the fact that, when thrombocytopenia was initially 
detected, surgery was done under platelet transfusion. In our bibliographic search, we 
found no other studies that analyzed this variable as a possible risk factor for recurrence. 
According to many authors, the placement of subdural closed-system drainage after 
BHC is associated with better outcomes (less recurrence and mortality rates) [1, 5, 7, 
20, 38]. Using a post-operative drain is currently becoming widespread, and it is 
deemed to be the standard procedure [1, 38]. According to our results, when comparing 
the group of patients who did not receive any post-operative drain with those who did 
receive a subdural or a subgaleal drain, the first group did not present a statistically 
significant or even a trend towards higher recurrence rate. This finding would be in 
agreement with that of Stanisic et al., who did not demonstrate any relationship between 
recurrence and use of drainage [32]. However, we found a trend towards the use of a 
subdural drain as a protective factor for CSDH recurrence. Most studies seem to find no 
overall statistically significant differences between subgaleal and subdural drainage [1, 
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5], but, according to Bellut et al., there may be a tendency towards a lower recurrence 
with placement of subdural drain [25], which is consistent with our result.   
Our mortality and morbidity rates were comparable to those found in the literature 
(7% and 11%, respectively) [1, 7]. Patients who had recurrent CSDH presented 
statistically significant higher morbidity rate, which emphasizes the need of reducing 
recurrence rates in order to achieve better outcomes to our patients. Recurrence was not, 
however, associated with higher mortality rates. 
 
2. Limitations 
Our study has some limitations that must be taken into account when interpreting 
the results. First, this was a retrospective study, subject to sources of bias and variation, 
mainly due to heterogeneity in records, resulting in a high number of missing data. 
Second, due to the sample size, there probably is a lack of adequate statistical power to 
detect a significant difference in variables studied. Third, there were multiple physicians 
involved in the surgical management of the patients with CSDH, and some operator-
associated variability may have been present. The decision for reoperation of the CSDH 
after initial surgery was also physician-dependent, and a different number of recurrent 
cases might have been obtained if a standardized guide would have been followed. 
3. Conclusions 
On the basis of our results, recurrence of CSDH after initial surgical evacuation was 
associated with increased morbidity rate. Patients who presented with recurrent CSDH 
and underwent further reoperation were significantly younger than patients who did not 
have recurrence. There was a trend towards a higher risk of recurrence in patients who 
were usually treated with anticoagulant drugs prior to the surgery, and in patients who 
did not receive a subdural post-operative drain. There was, however, no significant 
association between gender, bilateral CSDHs, usual medication with antiplatelet drugs 
prior to the surgery, thrombocytopenia prior to the surgery, use of subgaleal post-
operative drain or absence of post-operative drain and recurrence. 
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